Edition:
United Kingdom

Zymeworks Inc (ZYME.TO)

ZYME.TO on Toronto Stock Exchange

23.71CAD
24 May 2019
Change (% chg)

$-0.04 (-0.17%)
Prev Close
$23.75
Open
$24.58
Day's High
$24.58
Day's Low
$23.71
Volume
1,900
Avg. Vol
7,569
52-wk High
$30.36
52-wk Low
$14.34

Latest Key Developments (Source: Significant Developments)

Zymeworks Enters Zymelink Antibody-Drug Conjugate Platform Licensing Agreement With Iconic Therapeutics
Tuesday, 14 May 2019 

May 14 (Reuters) - Zymeworks Inc ::ZYMEWORKS ENTERS ITS FIRST ZYMELINK™ ANTIBODY-DRUG CONJUGATE PLATFORM LICENSING AGREEMENT WITH ICONIC THERAPEUTICS.ZYMEWORKS INC - ZYMEWORKS ELIGIBLE TO RECEIVE MILESTONE PAYMENTS, ROYALTIES, AND WORLDWIDE CO-PROMOTION RIGHTS.ZYMEWORKS INC - ZYMEWORKS ENTITLED TO A SHARE OF REVENUES IF ICONIC OUTLICENSES PROGRAM.ZYMEWORKS INC - AGREEMENT ALSO PROVIDES ZYMEWORKS CO-PROMOTION RIGHTS WITH INCREASED ROYALTIES FOR PRODUCTS DEVELOPED USING ADC PROGRAM..ZYMEWORKS - ENTERED LICENSING AGREEMENT GRANTING ICONIC THERAPEUTICS NON-EXCLUSIVE RIGHTS TO CO'S PROPRIETARY ZYMELINK ANTIBODY-DRUG CONJUGATE PLATFORM.  Full Article

Zymeworks Reports 2019 First Quarter Financial Results
Thursday, 2 May 2019 

May 2 (Reuters) - Zymeworks Inc ::ZYMEWORKS REPORTS 2019 FIRST QUARTER FINANCIAL RESULTS.ZYMEWORKS INC - REVENUE FOR THREE MONTHS ENDED MARCH 31, 2019 WAS $11.9 MILLION AS COMPARED TO $0.04 MILLION IN SAME PERIOD OF 2018.ZYMEWORKS INC - AS OF MARCH 31, 2019, HAD $180.3 MILLION IN CASH AND CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS.ZYMEWORKS INC QTRLY LOSS PER SHARE $0.43.  Full Article

Zymeworks Reports 2018 Year-End Financial Results
Wednesday, 6 Mar 2019 

March 6 (Reuters) - Zymeworks Inc ::ZYMEWORKS REPORTS 2018 YEAR-END FINANCIAL RESULTS.ZYMEWORKS INC - QTRLY EARNINGS PER SHARE $0.29.ZYMEWORKS INC - AS OF DECEMBER 31, 2018, HAD $200.2 MILLION IN CASH AND CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS..  Full Article

Zymeworks Announces Pricing Of Public Offering
Thursday, 7 Jun 2018 

June 6 (Reuters) - Zymeworks Inc ::ZYMEWORKS ANNOUNCES PRICING OF PUBLIC OFFERING.ZYMEWORKS INC- PRICING OF ITS PREVIOUSLY- ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 5,400,000 COMMON SHARES AT A PRICE OF US$15.75 PER COMMON SHARE.  Full Article

Zymeworks Reports Qtrly Net Income Per Common Share $1.29
Wednesday, 14 Mar 2018 

March 14 (Reuters) - Zymeworks Inc ::ZYMEWORKS REPORTS 2017 YEAR-END FINANCIAL RESULTS.ZYMEWORKS INC - QTRLY RESEARCH AND DEVELOPMENTAL COLLABORATIONS REVENUE $50.1 MILLION.ZYMEWORKS INC - QTRLY NET INCOME PER COMMON SHARE $1.29.  Full Article

Zymeworks Adds New Clinical Sites In Canada And U.S. For Ongoing Study
Wednesday, 28 Feb 2018 

Feb 28 (Reuters) - Zymeworks Inc ::ZYMEWORKS - ADDS NEW CLINICAL SITES IN CANADA AND U.S. FOR ONGOING ADAPTIVE PHASE 1 STUDY OF CO'S LEAD CLINICAL CANDIDATE, ZW25.  Full Article

Zymeworks reports third quarter loss of $0.65 per share
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Zymeworks Inc :Zymeworks reports third quarter 2017 financial results and provides business update.Revenues for three months ended September 30, 2017 were $0.1 million compared to $2.2 million for same period of 2016​.Qtrly ‍loss per share $0.65​.  Full Article

Zymeworks reports second quarter financial results
Tuesday, 8 Aug 2017 

Aug 9 (Reuters) - Zymeworks Inc --:Zymeworks reports second quarter 2017 financial results.Zymeworks Inc says net loss for three months ended June 30, 2017 was $11.0 million.Q2 revenue $1.3 million versus $6.3 million.  Full Article